119th Congress · introduced in the House · Sep 4, 2025
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Official title from Congress.gov
Latest action (Jul 21, 2026): Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Reported to House (Jul 2, 2026)
Stem Cell Therapeutic and Research Reauthorization Act of 2025
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
Considered under suspension of the rules. (consideration: CR H4642-4643)
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 629.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Biological and life sciences · Blood and blood diseases · Cell biology and embryology · Health programs administration and funding · Organ and tissue donation and transplantation
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsIntroduced in House
Introduced in House
Actions from Congress.gov, newest first.
Coverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
28 citations; showing the 25 most recently posted.
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$310,000
Spent on own lobbying
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barrie…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NEW YORK BLOOD CENTER ENTERPRISES · lobbying firm or registrant: ARNOLD & PORTER KAYE SCHOLER LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Budget/Appropriations
Amount not reported
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medical/Disease Research/Clinical Labs
Amount not reported
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
Amount not reported
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…propriations Billing and Coding classifications CAR-T Therapy Clarifications OMB Uniform Guidance Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Mo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$300,000
Spent on own lobbying
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Budget/Appropriations
$10,000
Paid to lobbying firm
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$10,000
Paid to lobbying firm
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NEW YORK BLOOD CENTER ENTERPRISES · lobbying firm or registrant: ARNOLD & PORTER KAYE SCHOLER LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 18, 2026 · issue area: Health Issues
$90,000
Paid to lobbying firm
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Mo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$320,000
Spent on own lobbying
Alleviating Barriers for Caregivers (House and Senate), S. 1227/H.R. 2491. Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Accelerating Kids Access to Care Act (House and Senate), S. 752/H.R. 1509. Credit for Caring Act (House and Senate), S. 925/H.R. 2036. Sickle Cell Dis…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…tions Revaccination of Immunosuppressed Patients H.R. 1509/S. 752, The Accelerating Kids Access to Care Act H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Budget/Appropriations
$10,000
Paid to lobbying firm
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$10,000
Paid to lobbying firm
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DUKE UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: SIDLEY AUSTIN LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$10,000
Paid to lobbying firm
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NEMOURS FOUNDATION - A FLORIDA NOT-FOR-PROFIT CORPORATION · lobbying firm or registrant: THE NEMOURS FOUNDATION - A FLORIDA NOT-FOR-PROFIT CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
…o 340B Issues related to maternal health S. 2355, Patients Deserve Price Tags Act H.R. 5469 & S. 2858, SHINE for Autumn Act H.R. 6238 & S. 3254 NIH IMPROVE Act H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION OF BLOOD BANKS, DBA ASSOCIATION FOR THE ADVANCEMENT OF BLOO · lobbying firm or registrant: AMERICAN ASSOCIATION OF BLOOD BANKS, DBA ASSOCIATION FOR THE ADVANCEMENT OF BLOOD & BIOTHERAPIES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Health Issues
Amount not reported
Stem Cell Therapeutic and Research Reauthorization Act (SCTRRA) (S. 4109/H.R. 5160)
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. View filing
NMDP · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$120,000
Paid to lobbying firm
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues Monitor…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…e Financial Toxicity NIH Funding Cancer Moonshot H.R. 1509/S. 752, The Accelerating Kids Access to Care Act H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$280,000
Spent on own lobbying
Alleviating Barriers for Caregivers (House and Senate), S. 1227/H.R. 2491. Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160. Accelerating Kids Access to Care Act (House and Senate), S. 752/H.R. 1509. Credit for Caring Act (House and Senate), S. 925/H.R. 2036. Sickle Cell Disease Com…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing